Cyclooxygenase-1 suppresses lipopolysaccharide-induced changes in rat gastric inducible nitric oxide synthase

Sonlee D. West, James W. Suliburk, Kenneth S. Helmer, David W Mercer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

OBJECTIVE: Both nitric oxide synthase (NOS) and cyclooxygenase (COX) have inducible isoforms that are up-regulated during inflammatory states. However, the interaction between these enzymes is not clearly understood. The objective was to clarify the interactions between NOS and COX in the rat gastric mucosa in the presence and absence of lipopolysaccharide. DESIGN: Laboratory study. SETTING: Medical school laboratory. SUBJECTS: Female Sprague-Dawley rats. INTERVENTIONS: We used nonselective and selective COX inhibitors to determine the role of COX on inducible NOS (iNOS) expression in the gastric mucosa. MEASUREMENTS AND MAIN RESULTS: The nonselective COX inhibitors salicylate and indomethacin enhanced the expression of iNOS in the rat gastric mucosa and exacerbated gastric injury in the presence of lipopolysaccharide, effects reversed by exogenous prostaglandin E2. Selective COX-1 inhibition with SC560 similarly increased gastric iNOS expression and exacerbated gastric injury, while the selective COX-2 inhibitor NS398 had no effect on iNOS expression or gastric injury in the presence of lipopolysaccharide. CONCLUSIONS: These data suggest that COX-1 derived prostaglandins exert an inhibitory effect on gastric iNOS during endotoxemia, and this may represent a potential cytoprotective mechanism not previously recognized for this enzyme, since up-regulation of iNOS is deleterious in some tissues.

Original languageEnglish (US)
Pages (from-to)572-579
Number of pages8
JournalCritical care medicine
Volume36
Issue number2
DOIs
StatePublished - Jan 1 2008

Fingerprint

Cyclooxygenase 1
Nitric Oxide Synthase Type II
Lipopolysaccharides
Stomach
Prostaglandin-Endoperoxide Synthases
Gastric Mucosa
Cyclooxygenase Inhibitors
Nitric Oxide Synthase
Wounds and Injuries
Endotoxemia
Salicylates
Cyclooxygenase 2 Inhibitors
Enzymes
Medical Schools
Dinoprostone
Indomethacin
Prostaglandins
Sprague Dawley Rats
Protein Isoforms
Up-Regulation

Keywords

  • Bile
  • Lipopolysaccharide
  • NS398
  • SC560
  • Salicylate

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Cyclooxygenase-1 suppresses lipopolysaccharide-induced changes in rat gastric inducible nitric oxide synthase. / West, Sonlee D.; Suliburk, James W.; Helmer, Kenneth S.; Mercer, David W.

In: Critical care medicine, Vol. 36, No. 2, 01.01.2008, p. 572-579.

Research output: Contribution to journalArticle

West, Sonlee D. ; Suliburk, James W. ; Helmer, Kenneth S. ; Mercer, David W. / Cyclooxygenase-1 suppresses lipopolysaccharide-induced changes in rat gastric inducible nitric oxide synthase. In: Critical care medicine. 2008 ; Vol. 36, No. 2. pp. 572-579.
@article{886ab9dc0d9b4880af36d96b26717c28,
title = "Cyclooxygenase-1 suppresses lipopolysaccharide-induced changes in rat gastric inducible nitric oxide synthase",
abstract = "OBJECTIVE: Both nitric oxide synthase (NOS) and cyclooxygenase (COX) have inducible isoforms that are up-regulated during inflammatory states. However, the interaction between these enzymes is not clearly understood. The objective was to clarify the interactions between NOS and COX in the rat gastric mucosa in the presence and absence of lipopolysaccharide. DESIGN: Laboratory study. SETTING: Medical school laboratory. SUBJECTS: Female Sprague-Dawley rats. INTERVENTIONS: We used nonselective and selective COX inhibitors to determine the role of COX on inducible NOS (iNOS) expression in the gastric mucosa. MEASUREMENTS AND MAIN RESULTS: The nonselective COX inhibitors salicylate and indomethacin enhanced the expression of iNOS in the rat gastric mucosa and exacerbated gastric injury in the presence of lipopolysaccharide, effects reversed by exogenous prostaglandin E2. Selective COX-1 inhibition with SC560 similarly increased gastric iNOS expression and exacerbated gastric injury, while the selective COX-2 inhibitor NS398 had no effect on iNOS expression or gastric injury in the presence of lipopolysaccharide. CONCLUSIONS: These data suggest that COX-1 derived prostaglandins exert an inhibitory effect on gastric iNOS during endotoxemia, and this may represent a potential cytoprotective mechanism not previously recognized for this enzyme, since up-regulation of iNOS is deleterious in some tissues.",
keywords = "Bile, Lipopolysaccharide, NS398, SC560, Salicylate",
author = "West, {Sonlee D.} and Suliburk, {James W.} and Helmer, {Kenneth S.} and Mercer, {David W}",
year = "2008",
month = "1",
day = "1",
doi = "10.1097CCM.0B013E318162958C",
language = "English (US)",
volume = "36",
pages = "572--579",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Cyclooxygenase-1 suppresses lipopolysaccharide-induced changes in rat gastric inducible nitric oxide synthase

AU - West, Sonlee D.

AU - Suliburk, James W.

AU - Helmer, Kenneth S.

AU - Mercer, David W

PY - 2008/1/1

Y1 - 2008/1/1

N2 - OBJECTIVE: Both nitric oxide synthase (NOS) and cyclooxygenase (COX) have inducible isoforms that are up-regulated during inflammatory states. However, the interaction between these enzymes is not clearly understood. The objective was to clarify the interactions between NOS and COX in the rat gastric mucosa in the presence and absence of lipopolysaccharide. DESIGN: Laboratory study. SETTING: Medical school laboratory. SUBJECTS: Female Sprague-Dawley rats. INTERVENTIONS: We used nonselective and selective COX inhibitors to determine the role of COX on inducible NOS (iNOS) expression in the gastric mucosa. MEASUREMENTS AND MAIN RESULTS: The nonselective COX inhibitors salicylate and indomethacin enhanced the expression of iNOS in the rat gastric mucosa and exacerbated gastric injury in the presence of lipopolysaccharide, effects reversed by exogenous prostaglandin E2. Selective COX-1 inhibition with SC560 similarly increased gastric iNOS expression and exacerbated gastric injury, while the selective COX-2 inhibitor NS398 had no effect on iNOS expression or gastric injury in the presence of lipopolysaccharide. CONCLUSIONS: These data suggest that COX-1 derived prostaglandins exert an inhibitory effect on gastric iNOS during endotoxemia, and this may represent a potential cytoprotective mechanism not previously recognized for this enzyme, since up-regulation of iNOS is deleterious in some tissues.

AB - OBJECTIVE: Both nitric oxide synthase (NOS) and cyclooxygenase (COX) have inducible isoforms that are up-regulated during inflammatory states. However, the interaction between these enzymes is not clearly understood. The objective was to clarify the interactions between NOS and COX in the rat gastric mucosa in the presence and absence of lipopolysaccharide. DESIGN: Laboratory study. SETTING: Medical school laboratory. SUBJECTS: Female Sprague-Dawley rats. INTERVENTIONS: We used nonselective and selective COX inhibitors to determine the role of COX on inducible NOS (iNOS) expression in the gastric mucosa. MEASUREMENTS AND MAIN RESULTS: The nonselective COX inhibitors salicylate and indomethacin enhanced the expression of iNOS in the rat gastric mucosa and exacerbated gastric injury in the presence of lipopolysaccharide, effects reversed by exogenous prostaglandin E2. Selective COX-1 inhibition with SC560 similarly increased gastric iNOS expression and exacerbated gastric injury, while the selective COX-2 inhibitor NS398 had no effect on iNOS expression or gastric injury in the presence of lipopolysaccharide. CONCLUSIONS: These data suggest that COX-1 derived prostaglandins exert an inhibitory effect on gastric iNOS during endotoxemia, and this may represent a potential cytoprotective mechanism not previously recognized for this enzyme, since up-regulation of iNOS is deleterious in some tissues.

KW - Bile

KW - Lipopolysaccharide

KW - NS398

KW - SC560

KW - Salicylate

UR - http://www.scopus.com/inward/record.url?scp=38549136463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549136463&partnerID=8YFLogxK

U2 - 10.1097CCM.0B013E318162958C

DO - 10.1097CCM.0B013E318162958C

M3 - Article

VL - 36

SP - 572

EP - 579

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 2

ER -